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The trafficking of G protein coupled-receptors (GPCRs) is one of the most exciting areas in cell
biology because of recent advances demonstrating that GPCR signaling is spatially encoded.
GPCRs, acting in a diverse array of physiological systems, can have differential signaling conse-
quences depending on their subcellular localization. At the plasma membrane, GPCR organiza-
tion could fine-tune the initial stages of receptor signaling by determining the magnitude of
signaling and the type of effectors to which receptors can couple. This organization is mediated
by the lipid composition of the plasma membrane, receptor-receptor interactions, and receptor
interactions with intracellular scaffolding proteins. GPCR organization is subsequently changed
by ligand binding and the regulated endocytosis of these receptors. Activated GPCRs can modu-
late the dynamics of their own endocytosis through changing clathrin-coated pit dynamics, and
through the scaffolding adaptor protein β-arrestin. This endocytic regulation has signaling con-
sequences, predominantly through modulation of the MAPK cascade. This review explores what
is known about receptor sorting at the plasma membrane, protein partners that control receptor
endocytosis, and the ways in which receptor sorting at the plasma membrane regulates down-
stream trafficking and signaling.
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1 | INTRODUCTION
The organization and trafficking of G protein-coupled receptors
(GPCRs) at the cell membrane are major regulators of receptor signal-
ing. Because many GPCRs primarily respond to extracellular ligands, a
receptor's ability to respond to signals depends on its physical pres-
ence at the cell membrane.1 The spatial organization of receptors at
the cell membrane is tightly controlled, as reported by an increasing
number of studies. Receptor organization is likely dictated by the bio-
chemical properties of the receptors themselves,2 lipid composition of
the membrane,3 and the presence of a host of scaffolding proteins,4
although the mechanisms are still being elucidated. Once receptors
bind a ligand, receptors rapidly reorganize to specific domains within
the plasma membrane, which could help coordinate spatially restricted
signaling.5,6 GPCRs are further regulated at the cell surface by
agonist-mediated endocytosis.7 After activation, receptors are sorted
to endocytic domains through binding to the adaptor protein
β-arrestin.8,9 Many GPCRs continue to signal during endocytosis, making
use of β-arrestin as a signaling scaffold.10,11 Some GPCRs appear to reg-
ulate their own endocytic rate through modulation of clathrin-coated pit
(CCP) maturation.12–14 This regulation, which can differ between ligands
acting at the same GPCR, is an additional method by which GPCR sig-
naling can be spatially encoded.
This review explores our currently emerging understanding of
how receptors are organized on the membrane, and how this organi-
zation could regulate downstream trafficking and signaling. We focus
specifically on basal receptor localization and agonist-dependent
redistribution, as well as the mechanics of GPCR modulation of
receptor-mediated endocytosis of mammalian GPCRs. We also high-
light currently open questions in the field relating to how GPCR locali-
zation and trafficking at the plasma membrane has physiological
significance. Although the principles discussed focus on GPCR signal-
ing specifically, they are applicable to many other signaling receptors
or transmembrane proteins whose functions depend on spatial
localization.
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2 | BASAL RECEPTOR LOCALIZATION AND
AGONIST-DEPENDENT REDISTRIBUTION
GPCR organization in the plasma membrane is driven through receptor-
receptor, receptor-lipid and receptor-protein interactions that restrict
and regulate receptor movement within the plasma membrane
(Figure 1). Most GPCRs begin their signaling lives at the plasma mem-
brane, although some receptors are basally localized to intracellular sites
such as the ER or the trans Golgi network.15–17 Once delivered to the
plasma membrane, the three types of receptor interactions described
below help GPCRs localize to specialized membrane domains and
to specialized structures such as the neuronal postsynaptic density,18
primary cilia,19 and the outer segment of photoreceptor cells.20
2.1 | Receptor-receptor interactions
Despite a great deal of controversy over the past several decades,
there is mounting evidence for the existence of semi-stable oligomeric
GPCR complexes, as well as receptor-receptor interactions that drive
receptor signaling and localization.21,22 Some of these interactions are
stable and long-lasting,23,24 while some are transient and weak.25
These receptor-receptor interactions can produce homodimers of the
same receptor,26 or heterodimers of two different receptors.27 Homo-
dimerization is evolutionarily conserved. The yeast α-factor receptor
(Ste2p) shows a significant tendency to dimerize,28,29 and dimerization
of functional receptors might be required for receptor signaling.30
Dimeric receptor complexes can even couple to a single G protein or
arrestin molecule, as demonstrated for the light-activated GPCR rho-
dopsin.31,32 Heteromers such as the μ-/κ-opioid receptor (μOR, κOR)
dimer might couple to different effectors and induce functional
effects distinct from their monomers.33–36 Receptors can oligomerize
at multiple steps throughout the biosynthetic trafficking of GPCRs,
with the γ-aminobutyric acid receptor type B (GABABR) requiring
dimerization for endoplasmic reticulum (ER) export37,38 whereas
Ste2p dimerizes only at the plasma membrane.39
Receptor oligomerization regulates the diffusion of the receptors
within the plasma membrane. The GABAB receptor, an obligate
dimer,23,24 diffuses slowly within the plasma membrane and primarily
exists as dimers and tetramers.40 The β1-adrenergic receptor (B1AR)
exists predominantly as a monomer at the plasma membrane and the
closely related β2-adrenergic receptor splits its time roughly equally
between monomeric and dimeric states.40 Receptor oligomerization is
highly dynamic at physiological concentrations of receptor, as demon-
strated by recent studies with the neurotensin receptor NTSR141 and
rhodopsin.42 Changes in diffusion rate may serve to change receptor-
effector coupling, and GPCR-G protein complexes appear to diffuse
much more rapidly than GPCRs alone.43
2.2 | Receptor-lipid interactions
Receptor-lipid interactions can regulate receptor distribution at the
plasma membrane, and potentially affect receptor signaling. Fluores-
cence correlation spectroscopy of the μOR and κOR showed that
these receptors are enriched in cholesterol-rich domains and tend to
be excluded from ganglioside-rich plasma membrane domains.3 Some
GPCRs contain a cholesterol binding site,44 and cholesterol has been a
necessary additive to GPCR crystallization studies.45,46 Further evi-
dence suggests that cholesterol is permissive of GPCR GEF activity at
G proteins.47–49 Despite evidence showing a biochemical role of cho-
lesterol in GPCR activity, the exact function of GPCRs residing at
cholesterol-enriched membrane sites remains unknown. As heterotri-
meric G proteins can be differentially lipidated via palmitoylation, myr-
istoylation, farnesolyation and geranylgeranylation,50 it is possible
that GPCR localization to different lipid microdomains could dictate
coupling to different G proteins. Indeed, B2AR, which is predomi-
nantly coupled to Gαs,51 can couple to Gαi when restricted to lipid
rafts.52 Receptor-lipid interactions could therefore sort GPCRs to
FIGURE 1 GPCR organization at the plasma membrane is dynamic and regulated. (a) Before agonist addition, many GPCRs exist at the plasma
membrane as monomers. (b) Through receptor-receptor interactions, some receptors dynamically exchange between monomeric and oligomeric
states, with the degree of time a receptor spends in each of these states varying between different types of receptors. Receptors are enriched at
cholesterol-rich regions (darker blue) through receptor-lipid interactions, although they can diffuse between these domains and the surrounding
membrane. (c) After agonist addition, receptors cluster in clathrin-coated pits, regardless of their oligomeric state, but the rate at which a given
receptor is sorted into CCPs can be variable. The gray bars denote the clathrin coat. (d) Some receptors are obligate homodimers or heterodimers
or higher order oligomers, existing always in these states. (e) Receptor diffusion in the plasma membrane is restricted by actin and microtubule
“fences” (red rods) which confine receptors. (f ) Receptors can also cluster tightly together into domains that could mediate signaling after agonist
addition prior to localizing to CCPs. (g) Scaffolding proteins associate with and restrict the localization of certain GPCRs. Receptors bound to
scaffolding proteins may be protected from endocytosis
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membrane domains where receptors are best situated to signal
through different G proteins or even interact with specific effectors
or modifying enzymes, although this remains to be tested.
2.3 | Receptor-protein interactions
GPCR interactions with cytoskeletal and signaling scaffolds regulate
receptor organization at the plasma membrane. There are multitudes of
known GPCR interacting proteins,4,53 but only a subset of these have
been shown to participate directly in basal GPCR organization. GPCR
localization to neuronal synapses has received particular attention. The
localization of the metabotropic glutamate receptor 5 (mGluR5) is
dependent on the scaffolding protein Homer.54 Another metabotropic
glutamate receptor, mGluR7, is restricted to synapses through its inter-
action with the protein PICK1.55 This interaction is dependent on
PICK1's PSD-95/Dlg/ZO-1 (PDZ) homology domain, which binds a
PDZ ligand at the distal C-terminus of mGluR7. PSD-95, another PDZ
domain-containing protein, binds to the β1-adrenergic receptor (B1AR)
and appears to increase surface expression of the GPCR.56 Many
GPCRs feature PDZ ligands,57 and as these receptors are explored fur-
ther in their native context in polarized cells it is likely many similar scaf-
folds to those described above will be discovered.
GPCR diffusion at the plasma membrane also appears to be regu-
lated by the cortical cytoskeleton. A “fence and picket” model of
membrane organization previously proposed suggests that the diffu-
sion of transmembrane protein “pickets” is limited within differently
sized membrane compartments that are demarcated by actin
“fences.”58 Single molecule studies of μOR59 showed that receptors
diffused in distinct membrane “compartments,” with straight line bar-
riers that were assumed to be actin filaments. These early findings
were recently reaffirmed when single molecule analysis of B2AR and
the α2a-adrenergic receptor (A2AR) showed that these receptors
avoid actin during their diffusion in the plasma membrane and that
their diffusion is restricted to actin-bounded compartments.2
2.4 | Agonist-dependent redistribution
Agonist binding and activation cause substantial reorganization of GPCRs
from the basal state. Receptor reorganization includes receptor cluster-
ing, as well changes in receptor diffusion kinetics. For example, the μOR
clusters upon activation with the endogenous-like ligand DAMGO, but
not after treatment with the exogenous ligand morphine.6 DAMGO-
dependent receptor clustering correlates with downstream signaling
through the mitogen-activated protein kinase (MAPK) cascade. Because
of this MAPK activation, these receptor clusters have been suggested to
be a specialized signaling domain. MAPK signaling from these putative
signaling domains requires cholesterol at the plasma membrane, although
whether receptor clustering independent of signaling requires cholesterol
is not clear. Changes in receptor organization after agonist binding have
been explored also at a single-molecule level. The Gαs-coupled B2AR
and the Gαi-coupled A2AR do not change their diffusive behavior upon
agonist activation, but their respective G proteins become more mobile.2
In this study, only a small fraction of both B2AR and A2AR molecules
were shown to rapidly sort into CCPs after agonist addition. In contrast
to B2AR and A2AR, the Gαi/o-coupled metabotropic glutamate receptor
mGluR3 (a class C GPCR with a much larger extracellular domain com-
pared to the class A B2AR and A2AR) significantly slows its diffusion
when bound to an agonist, and sees considerable redistribution into
CCPs after agonist treatment.43 The variability between GPCRs suggests
that although there may be commonalities to how receptors behave
immediately following agonist treatment, receptor redistribution patterns
are worth investigating at the level of specific receptor types.
3 | AGONIST-MEDIATED RECEPTOR
ENDOCYTOSIS
The role and regulation of endocytosis—a well-known consequence of
receptor activation—is currently being redefined in the field. Activated
receptors are phosphorylated by G protein-receptor kinases, after which
they recruit the adapter protein β-arrestin.1,60 β-Arrestin binding sorts
receptors into CCPs—specialized endocytic domains on the plasma
membrane.8,61,62 The traditional view of GPCR endocytosis (excellently
reviewed previously63) was that it primarily served to desensitize recep-
tors after agonist activation by removing them from the cell surface.
Recent work has highlighted several novel aspects of GPCR endocytic
trafficking: (a) GPCRs segregate to specialized endocytic domains,
(b) GPCRs regulate the maturation of these endocytic domains and
(c) this regulation has signaling consequences that differ both between
receptors and between ligands acting at the same receptor. These
recent advances, discussed below, are summarized in Figure 2.
3.1 | Segregation of GPCRs in endocytic domains
Understanding GPCR regulation of endocytosis requires a broad
understanding of the steps of clathrin-mediated endocytosis (CME)
that GPCR cargo may be able to regulate. Endocytic cargo, including
GPCRs, is sorted into nascent CCPs through interaction with adaptor
proteins possessing both cargo- and clathrin-binding domains.
Although adaptor protein 2 (AP2) is the canonical adaptor for a host
of CME cargo, there are a variety of endocytic sorting signals and cog-
nate adaptors that bind them.64 CCP maturation to an internalized
vesicle is a highly regulated process.65,66 A maturing CCP proceeds
through multiple “checkpoints” before undergoing eventual dynamin-
dependent scission.67,68 Adaptor proteins play a prominent role in
implementing these checkpoints during CCP maturation.69,70
The diversity in both the number of cargoes internalized via CME
as well as the adaptor proteins used for this internalization suggests
that multiple routes for biochemically distinct CME pathways may
exist. Different cargo sorting signals for CME are differentially satura-
ble, indicating a variety of mechanisms for cargo association with cla-
thrin.71 Overexpression of distinct cargoes—the transferrin receptor
(TfR), the epidermal growth factor receptor (EGFR) and the low-
density lipoprotein receptor—can saturate each cargo's respective
endocytosis, but do not interfere with the endocytosis of the other
cargos.72,73 A straightforward explanation is that different cargoes
recruit distinct adapters and endocytic accessory proteins to nascent
CCPs. Consistent with this, the adaptor AP2 is required for the inter-
nalization of TfR but not EGFR.74 But the number of adaptors identi-
fied are far fewer than the number of potential cargoes. Alternatively,
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cargo could change the lipid environment in which CCPs form. For
example, EGFR-positive CCPs form preferentially from cholesterol
and sphingolipid-rich membrane rafts, a phenomenon which does not
appear to be conserved by other endocytic cargo.75
GPCRs can sort into specific subsets of CCPs. Activated B2AR
and μOR are present only in a subset of the CCPs through which TfR
endocytoses, both in fixed cell analyses and when visualizing endocy-
tosis at the resolution of single scission events, although the extent of
overlap between these cargo in the same CCPs has been variable
across studies.12,76–78 Furthermore, not all GPCRs sort to the same
subset of pits. The purinergic receptors P2Y1 and P2Y12 localize to dif-
ferent CCP subsets, with P2Y12 internalizing in the same CCPs as
B2AR while P2Y1 internalizes by a distinct clathrin-dependent path-
way.79 GPCRs and β-arrestin clusters that form at the cell membrane
in response to agonist colocalize with preexisting clathrin clusters,9
suggesting that GPCRs can cluster in a subset of extant CCPs as
opposed to exclusively nucleating specialized new CCPs. GPCRs also
show different biochemical requirements for endocytosis. Both P2Y12
and μOR require phosphorylated clathrin light chain for efficient CME,
whereas TfR does not.80,81 B2AR endocytosis is blocked at 16C
while TfR endocytosis is not.77 Segregation of different cargo into
specific subsets of CCPs could allow individual control over clustering
and endocytosis of different receptors.
3.2 | Receptor regulation of endocytosis
Regardless of the degree to which CCPs specialize based on cargo, it
is clear that GPCRs can regulate CCP dynamics.12,13,78 Although CCPs
containing the δ-opioid receptor (δOR) last ~40 seconds at the plasma
membrane before undergoing dynamin-dependent scission, CCPs
containing a chimeric δOR with B1AR's C-terminal PDZ ligand last
three times as long. CCPs containing B2AR, which has its own PDZ
ligand, also last longer than CCPs containing δOR. PDZ ligands extend
the duration of “CCPs lifetimes” by delaying dynamin recruitment at
the CCPs in which these receptors reside.12 However, work with μOR
has shown that this is not the only mechanism by which GPCRs can
regulate CCP lifetimes. μOR promotes long CCP lifetimes by delaying
scission after dynamin recruitment.78 Despite differing mechanisms,
both of these studies pinpointed receptor control of CCP lifetimes as
being mediated through amino acid motifs in the C-termini of the
identified receptors (PDZ ligands “DSLL” or “ESKV” for B2AR and db1,
a unique “LENLEAE” motif for μOR). How these sequences regulate
CCP dynamics is not known. The dynamin-dependent scission at the
end of vesicle maturation could be a point at which CME can be regu-
lated. The protein kinase Src phosphorylates dynamin2 and the actin
nucleating factor cortactin to be permissive of TfR endocytosis.82 The
kinase GSK3B also regulates dynamin activity through inactivating
phosphorylation of dynamin1.83 Interestingly, these kinases could be
FIGURE 2 GPCRs modulate endocytosis at distinct phases of the endocytic process. (a) After ligand binding to a given receptor, β-arrestin is
recruited to the receptor at the plasma membrane. (b) In the case of B1AR, an interaction between β-arrestin and the B1AR core region causes
β-arrestin to sort to clathrin-coated pits (CCPs) independent of the receptor. Other GPCRs sort with arrestin to CCPs. (c) P2Y12 and μOR regulate
clathrin light chain (CLC) phosphorylation through the activation of GPCR related kinases (GRKs) which is permissive of endocytosis continuing.
(d) After receptors are sorted into nascent CCPs, μOR is “proofread” by Epsin1 to ensure that it is ubiquitinated before CCP maturation continues.
At about the same phase, the PDZ ligand of B2AR delays recruitment of the GTPase dynamin through an unknown protein partner. (e) After
dynamin recruitment, μOR can delay dynamin-dependent scission through an unknown protein interacting with its C-terminal LENLEAE motif.
CB1R, through an arrestin interaction mediated by two serines on its C-terminal tail, can also delay CCP lifetimes. (f ) Through as yet unknown
mechanisms, GPCR interactions with PDZ domain-containing proteins can globally upregulate (eg, CRFR1 and PDZK1) or downregulate (eg,
mGluR1 and spinophilin) receptor internalization
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regulated by GPCRs themselves, providing a potential feedback mech-
anism for precise control of endocytic dynamics at the level of
individual CCPs.
Different ligands acting at the same receptor have distinct effects
on CCP lifetimes, pointing to the physiological relevance of CCP regu-
lation. This was first shown with the cannabinoid receptor 1 (CB1R),
where the exogenous ligand WIN 55212-2 caused shorter CCP life-
times than the endogenous ligand 2-arachidonoylglycerol (2-AG).13
Subsequent work with μOR revealed that the clinically relevant ligand
morphine produced significantly shorter endocytic lifetimes compared
to endomorphin-2, one of the receptor's endogenous agonists.14 For
both CB1R and μOR, longer receptor cluster lifetimes correlated with
increased MAPK activation, suggesting that CCPs sustain a signaling
complex that links receptors to MAPK, as discussed below.
GPCRs regulate endocytosis through their downstream signaling
and interactions with scaffolding proteins. In the case of P2Y12 and
μOR it is possible that activation of GPCR-regulated kinases (GRKs)
downstream of these receptors might regulate endocytosis in general
by changing the phosphorylation state of clathrin light chain, but it
remains unclear whether this phosphorylation plays a role in changing
CCP lifetimes.80 When investigating protein partners that might
mediate GPCR control of lifetimes, the PDZ ligands of the
β-adrenoreceptors provide tantalizing targets given their requirement
for lifetime extension, but no PDZ domain-containing partner has
been identified that regulates CCP lifetimes for these receptors. How-
ever, a host of other GPCRs have been shown to have PDZ-
dependent regulation of their endocytosis, although not specifically
though regulating CCP lifetimes. The PDZ ligands of the serotonin 2A
receptor (5HT2AR) and the corticotropin releasing factor receptor
1 (CRFR1) both bind the PDZ domain-containing protein synapse
associated protein 97 (SAP97), and overexpression of SAP97 slowed
global endocytic rate for both of these receptors.84,85 For CRFR1
alone, expression of the protein PDZK1 increased the receptor's
endocytic rate,86 while PSD-95 expression decreased the receptor's
endocytic rate87 in a manner consistent with the stabilizing effect
PSD-95 has on B1AR.56 Another GPCR, the metabotropic glutamate
receptor 1 (mGluR1), interacts with the PDZ domain-containing pro-
tein spinophilin and has subsequently decreased endocytosis. The
parathyroid hormone receptor (PTHR) interacts with the Na/H-
exchanger regulatory factor 1 (NHERF1) through a PDZ domain-
dependent interaction, and NHERF1 inhibits internalization of PTHR
following agonist treatment.88 These are only a handful of examples
of PDZ domain-containing proteins known to regulate GPCR internali-
zation. For all of these PDZ interactions, it has not yet been investi-
gated whether these effects on endocytosis are mediated through
extension of CCP lifetimes or through blocking receptors from sorting
into CCPs in the first place, although published results with B2AR's
extended CCP lifetimes make this a tantalizing question.
3.3 | Signaling consequences of receptor-regulated
endocytosis
The signaling effects of GPCR-mediated extension of lifetimes are pri-
marily mediated through β-arrestins. For CB1R, a receptor mutant that
binds β-arrestin1 more strongly than the wild-type receptor also
increases CCP lifetimes of the exogenous ligand WIN 55212-2.89
These extended lifetime CCPs produce stronger MAPK activation
downstream of β-arrestin as measured by phosphorylation of the
MAP kinases ERK 1 and 2.13 Extended lifetimes downstream of
endogenous agonists at μOR also serve to extend the duration of the
receptor/arrestin interaction and to increase ERK1/2 activation.14
Recent work has shown that following activation of B1AR, β-arrestin
can translocate to CCPs even in the absence of GPCR translocation.
These arrestin-positive CCPs subsequently have significantly pro-
longed lifetimes and this result in increased ERK1/2 phosphorylation
downstream of B1AR agonists.90 This discovery was extended by
showing that GPCRs can act as β-arrestin activators without necessi-
tating a stable interaction between the receptor and β-arrestin.91,92
This implicates GPCRs as not just cargo, but also regulators of protein
trafficking themselves. All of the above findings fit with an emerging
model whereby GPCRs affect multiple modes of β-arrestin function
through interactions at functionally distinct sites.93,94 Notably, the
dependence of ERK1/2 activation on lengthened endocytic lifetimes
has so far been demonstrated only with receptors whose activation of
MAPK is dependent on β-arrestin.
Several receptors that rely on PDZ domain-containing proteins to
regulate their endocytosis show positive coupling between endocyto-
sis and ERK1/2 activation. Studies with CRFR1 and 5HT2AR show
that the PDZ domain-containing protein SAP97 slows the endocytic
rate of these receptors while increasing their ligand-dependent
ERK1/2 activation.84,85 However, the effects of PDZ domain-
containing protein on receptor trafficking and signaling are not always
so stereotyped. For example, PDZK1 overexpression increases CRFR1
ERK1/2 activation while having no effect on CRFR1 endocytosis, but
this same overexpression increases 5HT2AR ERK1/2 activation while
slowing 5HT2AR endocytosis.86 The uncoupling of ERK1/2 activation
to endocytic lifetimes suggests that, at least for some receptors pro-
longed endocytic rate may serve a different role.
There is a dearth of evidence directly connecting endocytic life-
times to specific protein components in the MAPK cascade. Studies
exploring PDZ-dependent modulation of endocytosis and ERK1/2
have not demonstrated a direct interaction between any PDZ
domain-containing scaffolds and components of the MAPK
cascade.4,84–87,95,96 For some GPCRs, β-arrestin is required for con-
necting endocytic lifetimes to ERK1/2 activation. But the specific
molecular mechanism through which β-arrestin controls ERK1/2 acti-
vation is not clear.13,14,90 Differences in endocytic lifetimes may also
contribute to further downstream spatial encoding of GPCR signaling.
The recent explosion in the study of GPCR endosomal signaling
(recently reviewed97) opens up the exciting possibility that changes in
receptor duration on the plasma membrane might affect trafficking at
post-endocytic stages of GPCR trafficking.
The changes on the receptors that drive control of endocytic life-
times are not clear. One potential mechanism through which endocy-
tic lifetimes might regulate downstream trafficking is through
regulating the phosphorylation state of GPCRs. GPCR phosphoryla-
tion changes in response to agonist, and receptor phosphorylation is a
known regulator of GPCR trafficking and signaling. GPCRs are phos-
phorylated by many kinases including GRKs98–101 and PKA.101–103
Receptor phosphorylation begins at the plasma membrane
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independent of endocytosis,104 and at least some phosphorylation is
present on receptors throughout post-endocytic trafficking.105,106
Receptor phosphorylation is important for post-endocytic traffick-
ing107,108 and for endosomal receptor signaling.109 Modulating GPCR
ubiquitination is another potential target of endocytic lifetime regula-
tion. Ubiquitination has been implicated in GPCR trafficking and sig-
naling (reviewed by Trejo and coworkers in this same issue). The
endocytosis of yeast GPCRs Ste2p and Ste3p depends on ubiquitina-
tion, after which they might recruit alpha arrestins or other unique
adapters. Ubiquitination plays a prime role in the p38 signaling down-
stream of the protease activated receptor 1.110 Ubiquitination is
required for effective β-arrestin recruitment at the interleukin-8 che-
mokine receptor (CXCR2),111 and for regulating the dynamics of inter-
nalization of the μOR.112 The latter mechanism is mediated through
an ubiquitin binding motif in the endocytic accessory protein Epsin1,
suggesting that cells proofread receptor modification states before
allowing the receptor to internalize.
In summary, GPCRs are not passive components in endocytic
trafficking. Rather, they can control the dynamics of endocytic compo-
nents. This control might modulate downstream signaling pathways
including the MAPK pathway. It is possible that the endocytic life-
times indirectly regulate the phosphorylation or ubiquitination states
of receptors themselves, which in turn could regulate interactions of
receptors with components of the endocytic pathway, although there
is little evidence to support this model at present. The interplay
between signaling and endocytic control is an area with tremendous
potential that still needs to be understood better.
4 | CONCLUDING REMARKS AND FUTURE
DIRECTIONS
In the past decade, we have learnt much about GPCR organization at
the plasma membrane, but much still remains to be learned both with
regards to the nature of basal organization, the mechanism of endocy-
tic regulation, and the physiological effects of both. For example,
while targets such as PDZ proteins and β-arrestins have been con-
firmed, we do not understand how these interactions modify CME.
Furthermore, ERK1/2 is the main signaling output that has been mea-
sured downstream of CCP regulation, but the physiological conse-
quences of ERK1/2 activation remain unknown. Nevertheless, current
work has uncovered the potential physiological and translational
impact of spatial organization of signaling receptors and has under-
lined the importance of studying receptor trafficking. Another inter-
esting aspect that still needs to be addressed is the contribution of
GPCR reorganization and endocytic control on how different ligands
acting at the same receptor can bias downstream signaling to different
effector-driven pathways—a phenomenon termed biased agonism or
functional selectivity.113 Although the correlation of endocytic life-
times and arrestin-mediated activation of MAPK suggest a mechanism
through which different agonists may produce bias, the exploration of
how membrane organization relates to bias is still in its infancy. Learn-
ing how receptor partitioning into lipid domains regulates signaling, or
how receptor oligomerization is regulated, may also be key to under-
standing the pleiotropy of signaling and mechanisms of bias.
The next frontier is to validate the importance of the mechanistic
findings discussed to receptor physiology in vivo. Model cells, where
receptors can be heterologously expressed, receptors and effectors
specifically mutated or modified, and signaling outputs isolated, have
been indispensable in understanding the fundamental principles of
receptor organization and trafficking. Nevertheless, as we continue to
use these models to tease out mechanistic details, a concomitant step
is to move the study of receptor localization and function into physio-
logically relevant systems expressing endogenous receptors. Some of
the receptor-lipid, receptor-receptor and receptor-protein interactions
have been demonstrated directly in primary cells of interest. At pre-
sent, the degree of endocytic specialization in primary cells and the
role of endocytic regulation are still not well understood. Newer
advances in imaging and profiling receptor location and signaling and
in inducible stem cells, as well as using animal models with cell-specific
expression and gene-editing tools, provide exciting avenues for
addressing the role of spatial organization in receptor physiology
in vivo. As we continue to validate findings in specific physiological
systems, we anticipate that this will open a new druggable proteome,
allowing pharmaceutical targeting of trafficking factors to regulate the
endogenous signaling of GPCRs that are important in physiology and
disease.
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